riboxx´s expertise is to design, engineer and manufacture RNA (ribonucleic acid).
This expertise translates in two business lines:
riboxx life sciences, that develops, produces and markets novel reagents used by scientists in research and development
riboxx pharmaceuticals, that manufactures under cGMP guidelines novel immunomodulators for therapeutic vaccines (against cancer) and prophylactic vaccines (against infections)
riboxx life sciences: reagents for research and development
riboxx life sciences develops customized and tailor-made molecular tools for gene knockdown in vitro and in vivo through RNA interference: small interfering RNA (siRNA) and microRNA (miRNA). RNA interference is a new technology broadly used in life science. With the help of RNA interference, genotype-phenotype correlation studies as well as identification of gene expression patterns are possible.
riboxx life sciences has developed innovative molecular tools for gene silencing in vivo such as the IVORI® siRNA, the CONTRAmir® and CONmir®. riboxx´s technologies are robust, easy-to-use and reliable.
Additionnally, riboxx life sciences markets novel Toll-like-receptor 3 ligands (i.e. RIBOXXOL®) to scientists performing studies on immune cells such as maturation studies of dendritic cells or in vivo development of prophylactic or therapeutic vaccines.
riboxx pharmaceuticals: novel and unique drugs for immunotherapy
riboxx pharmaceuticals develops, manufactures and markets unique drugs for immunotherapy of cancer or virus diseases.
The drugs developed at riboxx act by switching the immune system ON. This is achieved by triggering activation of the so called "innate immune system". The innate immune system is the first line of defense of the body. It is also the oldest immune defense strategy, and is found in all classes of animal life. It is a non-specific immune system, (i.e. not specific for one pathogen), being triggered by molecular patterns, such as double-stranded RNA (dsRNA).
Immune cells playing an important role in innate immunity include dendritic cells, macrophages, neutrophils, and Natural Killer cells. These cells are directly implicated in mounting a potent immune response to cancer or virus infections.
The drugs developed at riboxx belong to the class of Toll-like-Receptor agonists (TLR) and RIG-I-like-Receptor (RLR) agonists. The Active Pharmaceutical Ingredient (API) of these drugs is RNA (Ribonucleic acid).
Additionnally, riboxx pharmaceuticals offers cGMP-Manufacturing of iVORi siRNA, CONmiR mimics in vivo and CONTRAmiR in vivo for its customers.